StockMacro
Company, fund or insider

Help

Menu

Sight Sciences

$10.18 +104% in 6 monthsMarket cap $565.8M

SGHT on XNAS, Health Care, Sight Sciences, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 25% to $24.9M and shares climbed 53% in a year.

  • GoodTwelve-month revenue rose 16% to $88.4M
  • BadNet loss of $28.4M over the last twelve months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
186
Website
sightsciences.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $24.9M, net loss $6.8M.
Quarter to 31 Dec 2021: revenue $14.7M, net income -$15.9MQuarter to 31 Dec 2021: revenue $14.7M, net income -$15.9MQuarter to 31 Mar 2022: revenue $14.9M, net income -$23.3MQuarter to 31 Mar 2022: revenue $14.9M, net income -$23.3MQuarter to 30 Jun 2022: revenue $17.2M, net income -$23.8MQuarter to 30 Jun 2022: revenue $17.2M, net income -$23.8MQuarter to 30 Sep 2022: revenue $18.7M, net income -$22.2MQuarter to 30 Sep 2022: revenue $18.7M, net income -$22.2MQuarter to 31 Dec 2022: revenue $20.5M, net income -$16.9MQuarter to 31 Dec 2022: revenue $20.5M, net income -$16.9MQuarter to 31 Mar 2023: revenue $18.8M, net income -$17.1MQuarter to 31 Mar 2023: revenue $18.8M, net income -$17.1MQuarter to 30 Jun 2023: revenue $23.5M, net income -$14.8MQuarter to 30 Jun 2023: revenue $23.5M, net income -$14.8MQuarter to 30 Sep 2023: revenue $20.0M, net income -$13.0MQuarter to 30 Sep 2023: revenue $20.0M, net income -$13.0MQuarter to 31 Dec 2023: revenue $18.8M, net income -$10.7MQuarter to 31 Dec 2023: revenue $18.8M, net income -$10.7MQuarter to 31 Mar 2024: revenue $19.3M, net income -$16.3MQuarter to 31 Mar 2024: revenue $19.3M, net income -$16.3MQuarter to 30 Jun 2024: revenue $21.4M, net income -$12.3MQuarter to 30 Jun 2024: revenue $21.4M, net income -$12.3MQuarter to 30 Sep 2024: revenue $20.2M, net income -$11.1MQuarter to 30 Sep 2024: revenue $20.2M, net income -$11.1MQuarter to 31 Dec 2024: revenue $19.1M, net income -$11.8MQuarter to 31 Dec 2024: revenue $19.1M, net income -$11.8MQuarter to 31 Mar 2025: revenue $17.5M, net income -$14.2MQuarter to 31 Mar 2025: revenue $17.5M, net income -$14.2MQuarter to 30 Jun 2025: revenue $19.6M, net income -$11.9MQuarter to 30 Jun 2025: revenue $19.6M, net income -$11.9MQuarter to 30 Sep 2025: revenue $19.9M, net income -$8.2MQuarter to 30 Sep 2025: revenue $19.9M, net income -$8.2MQuarter to 31 Dec 2025: revenue $20.4M, net income -$4.2MQuarter to 31 Dec 2025: revenue $20.4M, net income -$4.2MQuarter to 31 Mar 2026: revenue $19.7M, net income -$13.0MQuarter to 31 Mar 2026: revenue $19.7M, net income -$13.0MQuarter to 30 Jun 2026: revenue $23.4M, net income -$4.4MQuarter to 30 Jun 2026: revenue $23.4M, net income -$4.4MQuarter to 30 Sep 2026: revenue $24.9M, net income -$6.8MQuarter to 30 Sep 2026: revenue $24.9M, net income -$6.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $24.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$24.9M-$6.8M
30 Jun 2026$23.4M-$4.4M
31 Mar 2026$19.7M-$13.0M
31 Dec 2025$20.4M-$4.2M
30 Sep 2025$19.9M-$8.2M
30 Jun 2025$19.6M-$11.9M
31 Mar 2025$17.5M-$14.2M
31 Dec 2024$19.1M-$11.8M
30 Sep 2024$20.2M-$11.1M
30 Jun 2024$21.4M-$12.3M
31 Mar 2024$19.3M-$16.3M
31 Dec 2023$18.8M-$10.7M
30 Sep 2023$20.0M-$13.0M
30 Jun 2023$23.5M-$14.8M
31 Mar 2023$18.8M-$17.1M
31 Dec 2022$20.5M-$16.9M
30 Sep 2022$18.7M-$22.2M
30 Jun 2022$17.2M-$23.8M
31 Mar 2022$14.9M-$23.3M
31 Dec 2021$14.7M-$15.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $88.4M $76.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +16% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$28.4M -$46.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.52 -$0.91
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 87.7% 86.0% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -29.5% -59.6% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -32.1% -60.6% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -50.1% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$16.9M -$31.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $77.4M $92.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $48.4M $42.4M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$29.0M (net cash) -$50.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.99 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.88
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 6.4 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 6.1 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 11.5 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Sight SciencesSGHT (this company) $565.8Mloss6.4+16%-32.1%
Tactile Systems TechnologyTCMD $573.5M24.11.6+14%6.7%
Orchestra BioMedOBIO $517.9Mloss16.6+1007%-183%
Avita MedicalRCEL $495.0Mloss5.8+17%-42.7%
Delcath SystemsDCTH $653.7M98.25.9+38%6.1%
CarlsmedCARL $477.4Mloss6.7+60%-55.8%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+25%

$24.9M vs $19.9M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$873K

bought $0, sold $873K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+16%

129 13F filers vs 111

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

42%

23.1M shares held by 13F filers (30 Sep 2026) of 55.6M outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.0%

1.1M shares sold short (30 Oct 2026) of 55.6M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.3

1.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-8.5%

1.2M shares sold short in the report before, 1.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

24%

24% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 39%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$70K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

10

10 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

10×

10 articles in the last 7 days; its usual week has 1.

Price $10.18 on 20 Nov 2026, +53% over 12 months (12-month range $3.45 to $11.01)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $2.4M in the last 12 months (the 12 months before: -$61K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months, 0% on the 12 months before.
Revenue per quarter. Revenue $24.9M in the latest quarter, +25% on a year earlier.
Capital spending per quarter. Capital spending $68K in the latest quarter, -60% on a year earlier.
Institutional holders (13F filers). 129 13F filers reported holding it in the latest 13F quarter, +63% on a year earlier.
Lobbying spend. Lobbying spend: $70K published in the last 12 months, -22% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Aug 20268-K and other filingsDirector or officer change
10 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Apr 2026Lobbying filinglobbying engagement terminated (THE MCMANUS GROUP)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 11 (2025-12-31); 2.3x the same period a year earlier
6 Nov 20258-K and other filingsDirector or officer change
27 Aug 20258-K and other filingsDirector or officer change
27 Aug 20258-K and other filingsRestructuring costs announced
5 Jun 20258-K and other filingsDirector or officer change
8 May 2025Lobbying filingnew lobbying registration (THE MCMANUS GROUP)
22 Apr 20258-K and other filingsDirector or officer change
15 Apr 2025Sharp changeShort interest spike: short interest spike, 1.7M vs usual 1.1M (2025-03-31); 1.3x the same period a year earlier
1 Apr 2025Sharp changeShort interest spike: short interest spike, 1.9M vs usual 1.1M (2025-03-14); 1.2x the same period a year earlier
18 Mar 2025Sharp changeShort interest spike: short interest spike, 1.6M vs usual 1.1M (2025-02-28); 1.1x the same period a year earlier
28 Jan 20258-K and other filingsDirector or officer change
7 Nov 20248-K and other filingsDirector or officer change
7 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2024Lobbying filinglobbying engagement terminated (FOLEY HOAG LLP)
2 May 20248-K and other filingsCompleted an acquisition or asset sale
5 Apr 2024Lobbying filinglobbying engagement terminated (PATEL PARTNERS)
2 Feb 20248-K and other filingsDirector or officer change
2 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Feb 2024Sharp changeLobbying on a new issue: lobbying on a new issue: MMM (2023-12-31)
23 Jan 20248-K and other filingsA major agreement ended
26 Dec 2023Lobbying filingnew lobbying registration (PATEL PARTNERS)
15 Dec 2023Lobbying filingnew lobbying registration (FOLEY HOAG LLP)
17 Oct 20238-K and other filingsRestructuring costs announced
11 Sep 20238-K and other filingsDirector or officer change
11 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Jul 2023Lobbying filinglobbying engagement terminated (CAPITOL COUNSEL LLC)
3 Apr 20238-K and other filingsDirector or officer change
9 Jan 20238-K and other filingsDirector or officer change
9 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jul 2022Lobbying filinglobbying engagement terminated (AKIN GUMP STRAUSS HAUER & FELD)
19 Jul 20228-K and other filingsDirector or officer change
19 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Jul 2022Lobbying filinglobbying engagement terminated (PORTERFIELD, FETTIG & SEARS, LLC)
26 Apr 2022Lobbying filingnew lobbying registration (CAPITOL COUNSEL LLC)
16 Mar 20228-K and other filingsDirector or officer change
4 Mar 20228-K and other filingsDirector or officer change
4 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Feb 2022Lobbying filingnew lobbying registration (PORTERFIELD, FETTIG & SEARS, LLC)
Insider net buying (open market)
Month from 1 Nov 2021: $184K published
Month from 1 Dec 2021: $11.0M published
Month from 1 May 2022: $4.6M published
Month from 1 Nov 2023: $2.5M published
Month from 1 Dec 2023: -$16.2M published
Month from 1 Jan 2024: -$151K published
Month from 1 Apr 2024: -$173K published
Month from 1 May 2024: -$71K published
Month from 1 Jul 2024: -$219K published
Month from 1 Oct 2024: -$697K published
Month from 1 Nov 2024: $7K published
Month from 1 Dec 2024: $51K published
Month from 1 Jan 2025: -$233K published
Month from 1 Mar 2025: $53K published
Month from 1 Apr 2025: -$148K published
Month from 1 May 2025: $407K published
Month from 1 Jun 2025: $758K published
Month from 1 Jul 2025: -$259K published
Month from 1 Oct 2025: -$201K published
Month from 1 Nov 2025: -$489K published
Month from 1 Dec 2025: $95K published
Month from 1 Jan 2026: -$877K published
Month from 1 Apr 2026: -$312K published
Month from 1 May 2026: -$65K published
Month from 1 Jun 2026: $69K published
Month from 1 Jul 2026: -$448K published
Month from 1 Oct 2026: -$653K published
Month from 1 Nov 2026: -$220K published
H-1B/E-3 applications certified
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2020: $9.0M; public on 25 Mar 2022
Quarter ended 31 Mar 2021: $8.6M; public on 11 May 2022
Quarter ended 31 Dec 2021: $14.7M, +63% on a year earlier; public on 25 Mar 2022
Quarter ended 31 Mar 2022: $14.9M, +72% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $17.2M, +37% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $18.7M, +43% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $20.5M, +40% on a year earlier; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $18.8M, +26% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $23.5M, +36% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $20.0M, +7.1% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $18.8M, -8.7% on a year earlier; public on 14 Mar 2024
Quarter ended 31 Mar 2024: $19.3M, +2.3% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $21.4M, -9.0% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $20.2M, +0.7% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $19.1M, +1.7% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $17.5M, -9.1% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $19.6M, -8.5% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $19.9M, -1.2% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $20.4M, +6.9% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $19.7M, +13% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $23.4M, +20% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $24.9M, +25% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $302K; public on 25 Mar 2022
Quarter ended 31 Mar 2021: $104K; public on 11 May 2022
Quarter ended 31 Dec 2021: $157K, -48% on a year earlier; public on 25 Mar 2022
Quarter ended 31 Mar 2022: $227K, +118% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $342K, +29% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $272K, -5.2% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $129K, -18% on a year earlier; public on 17 Mar 2023
Quarter ended 31 Mar 2023: $126K, -44% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $97K, -72% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $304K, +12% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $264K, +105% on a year earlier; public on 14 Mar 2024
Quarter ended 31 Mar 2024: $117K, -7.1% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $80K, -18% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $51K, -83% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $137K, -48% on a year earlier; public on 8 Mar 2025
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $210K, +162% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $170K, +233% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $60K; public on 7 May 2026
Quarter ended 30 Jun 2026: $19K, -91% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $68K, -60% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 58; public on 14 Feb 2022
31 Mar 2022 report: 64; public on 16 May 2022
30 Jun 2022 report: 64; public on 15 Aug 2022
30 Sep 2022 report: 66; public on 14 Nov 2022
31 Dec 2022 report: 61; public on 14 Feb 2023
31 Mar 2023 report: 74; public on 15 May 2023
30 Jun 2023 report: 69; public on 14 Aug 2023
30 Sep 2023 report: 62; public on 14 Nov 2023
31 Dec 2023 report: 60; public on 14 Feb 2024
31 Mar 2024 report: 63; public on 15 May 2024
30 Jun 2024 report: 68; public on 14 Aug 2024
30 Sep 2024 report: 75; public on 14 Nov 2024
31 Dec 2024 report: 81; public on 14 Feb 2025
31 Mar 2025 report: 73; public on 15 May 2025
30 Jun 2025 report: 77; public on 14 Aug 2025
30 Sep 2025 report: 79; public on 14 Nov 2025
31 Dec 2025 report: 105; public on 17 Feb 2026
31 Mar 2026 report: 107; public on 15 May 2026
30 Jun 2026 report: 111; public on 14 Aug 2026
30 Sep 2026 report: 129; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $100K published
Quarter from 1 Oct 2022: $50K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $40K published
Quarter from 1 Jan 2024: $50K published
Quarter from 1 Apr 2024: $20K published
Quarter from 1 Jul 2025: $40K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $20K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 129 (30 Sep 2026), 1.7× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $2.4M in the last 12 months (the 12 months before: -$61K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months, 0% on the 12 months before.
  • Revenue per quarter: Revenue $24.9M in the latest quarter, +25% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 6 sales, $873K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Brenton TaylorEVP, Operations & R&DSellplanned in advance (10b5-1)20,685$10.64$220KForm 4
5 Oct 2026Brenton TaylorEVP, Operations & R&DSellplanned in advance (10b5-1)2,988$8.85$26KForm 4
5 Oct 2026Alison BauerleinChief Operating OfficerSellplanned in advance (10b5-1)25,260$8.85$224KForm 4
5 Oct 2026James RodbergChief Financial OfficerSellplanned in advance (10b5-1)7,208$8.85$64KForm 4
5 Oct 2026David BadawiChief Technology OfficerSellplanned in advance (10b5-1)7,797$9.05$71KForm 4
5 Oct 2026Paul BadawiPresident and CEOSellplanned in advance (10b5-1)29,653$9.05$268KForm 4
6 Jul 2026James RodbergChief Financial OfficerSellplanned in advance (10b5-1)6,902$5.36$37KForm 4
6 Jul 2026David BadawiChief Technology OfficerSellplanned in advance (10b5-1)7,418$5.51$41KForm 4

129 institutions reported shares at the end of Q3 2026, 42% of the shares outstanding; 24 opened a position, 7 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Long Focus Capital Management, LLC3.8M6.92%$36.0MNo change
BlackRock, Inc.3.4M6.05%$31.5M+278K+9.0%
Pathstone Holdings, LLC2.2M3.93%$20.5M+508K+30%
Vanguard Capital Management LLC1.6M2.94%$15.3M+62K+3.9%
Geode Capital Management, LLC979K1.76%$9.2M+21K+2.1%
B Group, Inc.970K1.75%$9.1MNo change
Acadian Asset Management LLC844K1.52%+38K+4.7%
State Street Corp841K1.51%$7.9M+5,183+0.6%
Millennium Management LLC709K1.28%$6.6M+634K+842%
Dimensional Fund Advisors LP371K0.67%$3.5M-13K-3.3%

Company events

All 29 company events

In 12 months: 1 major agreement, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
10 Aug 2026Director or officer change8-K
3 Feb 2026Signed a major agreement8-K
6 Nov 2025Director or officer change8-K
30 Sep 2025Signed a major agreement8-K
27 Aug 2025Director or officer change; Restructuring costs announced8-K
5 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
22 Apr 2025Director or officer change8-K
28 Jan 2025Director or officer change8-K

Reported lobbying spend: $20K in Q1 2026, $50K in Q4 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
27 Jan 2026EndedThe Mcmanus Groupfor Sight SciencesIssues related to modernizing payment policy for comprehensive minimally invasive glaucoma surgery procedures.Medicare/MedicaidFiling
1 May 2025NewThe Mcmanus Groupfor Sight SciencesIssues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421-NC)Medicare/MedicaidFiling
30 Sep 2024EndedFoley Hoag LLPfor Sight SciencesMedicare reimbursement for minimally invasive glaucoma surgery procedures.Medicare/MedicaidFiling
26 Mar 2024EndedPatel Partnersfor Sight SciencesIssues pertaining to non-invasive ocular proceduresHealth issuesFiling
4 Dec 2023NewPatel Partnersfor Sight SciencesIssues related to both invasive and non-invasive eye diseases.Health issues, Medicare/Medicaid, MEDFiling
8 Nov 2023NewFoley Hoag LLPfor Sight SciencesMedicare reimbursement for minimally invasive glaucoma surgery procedures.Medicare/MedicaidFiling
30 Jun 2023EndedCapitol Counsel LLCfor Sight SciencesAdvocacy for coverage for Ophthalmology related procedures.Health issuesFiling
30 Jun 2022EndedAkin Gump Strauss Hauer & Feldfor Sight Sciences, Inc.Not statedFiling

The 5 newest of 62 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 10 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 10 Aug 2026Filings record

    Director or officer change

  3. 12 Jun 2026Insiders record

    Encrantz Staffan (director) bought 14,100 shares of SGHT ($68,808) (dated 11 Jun 2026)

  4. 20 Apr 2026Lobbying record

    SIGHT SCIENCES: lobbying engagement terminated (THE MCMANUS GROUP) (dated 27 Jan 2026)

  5. 17 Feb 2026Institutional holdings change

    saw 30 13F filers open a new position in the quarter ended 31 Dec 2025, 2.3× the same quarter last year.

    Same quarter last year: 13; its normal quarter is 11.

    See the evidence
    This period
    30 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    11
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +6.3
    Same quarter last year
    13
    History used
    1,553 days
    2023-12-31: 152024-03-31: 112024-06-30: 132024-09-30: 92024-12-31: 132025-03-31: 92025-06-30: 112025-09-30: 92025-12-31: 30
    the quarter ended 31 Dec 20258 earlier quartersnormal: 11

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 19 Dec 2025Insiders record

    Encrantz Staffan (director) bought 13,958 shares of SGHT ($115,991) (dated 18 Dec 2025)

  7. 6 Nov 2025Filings record

    Director or officer change

  8. 27 Aug 2025Filings record

    Director or officer change

  9. 27 Aug 2025Filings record

    Restructuring costs announced

  10. 7 Jun 2025Insiders record

    Encrantz Staffan (director) bought 90,525 shares of SGHT ($381,751) (dated 6 Jun 2025)

  11. 5 Jun 2025Filings record

    Director or officer change

  12. 4 Jun 2025Insiders record

    Encrantz Staffan (director) bought 98,782 shares of SGHT ($376,567) (dated 3 Jun 2025)

  13. 30 May 2025Insiders record

    Encrantz Staffan (director) bought 128,189 shares of SGHT ($452,127) (dated 29 May 2025)

  14. 8 May 2025Lobbying record

    SIGHT SCIENCES: new lobbying registration (THE MCMANUS GROUP) (dated 1 May 2025)

  15. 22 Apr 2025Filings record

    Director or officer change

  16. 10 Apr 2025Short interest and volume change

    had 1.7M shares sold short in the 31 Mar 2025 report, 1.3× the same report last year.

    Same report last year: 1.3M; its normal report is 1.1M.

    See the evidence
    This period
    1.7M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    77K
    How far from its usual level
    +5.1
    Same report last year
    1.3M
    History used
    1,340 days
    2024-03-28: 1.3M2024-04-15: 1.3M2024-04-30: 1.4M2024-05-15: 1.2M2024-05-31: 1.2M2024-06-14: 1.1M2024-06-28: 1.1M2024-07-15: 1.3M2024-07-31: 1.2M2024-08-15: 1.1M2024-08-30: 1.1M2024-09-13: 1.0M2024-09-30: 1.1M2024-10-15: 1.1M2024-10-31: 1.1M2024-11-15: 977K2024-11-29: 985K2024-12-13: 1.1M2024-12-31: 1.1M2025-01-15: 1.1M2025-01-31: 1.2M2025-02-14: 1.4M2025-02-28: 1.6M2025-03-14: 1.9M2025-03-31: 1.7M
    the 31 Mar 2025 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 26 Mar 2025Short interest and volume change

    had 1.9M shares sold short in the 14 Mar 2025 report, 1.2× the same report last year.

    Same report last year: 1.6M; its normal report is 1.1M.

    See the evidence
    This period
    1.9M (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    77K
    How far from its usual level
    +6.9
    Same report last year
    1.6M
    History used
    1,323 days
    2024-03-15: 1.6M2024-03-28: 1.3M2024-04-15: 1.3M2024-04-30: 1.4M2024-05-15: 1.2M2024-05-31: 1.2M2024-06-14: 1.1M2024-06-28: 1.1M2024-07-15: 1.3M2024-07-31: 1.2M2024-08-15: 1.1M2024-08-30: 1.1M2024-09-13: 1.0M2024-09-30: 1.1M2024-10-15: 1.1M2024-10-31: 1.1M2024-11-15: 977K2024-11-29: 985K2024-12-13: 1.1M2024-12-31: 1.1M2025-01-15: 1.1M2025-01-31: 1.2M2025-02-14: 1.4M2025-02-28: 1.6M2025-03-14: 1.9M
    the 14 Mar 2025 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 14 Mar 2025Insiders record

    Raheja Manohar K. (EVP, Research & Development) bought 20,000 shares of SGHT ($53,300) (dated 13 Mar 2025)

  19. 12 Mar 2025Short interest and volume change

    had 1.6M shares sold short in the 28 Feb 2025 report, 1.1× the same report last year.

    Same report last year: 1.4M; its normal report is 1.1M.

    See the evidence
    This period
    1.6M (the 28 Feb 2025 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    77K
    How far from its usual level
    +3.8
    Same report last year
    1.4M
    History used
    1,309 days
    2024-02-29: 1.4M2024-03-15: 1.6M2024-03-28: 1.3M2024-04-15: 1.3M2024-04-30: 1.4M2024-05-15: 1.2M2024-05-31: 1.2M2024-06-14: 1.1M2024-06-28: 1.1M2024-07-15: 1.3M2024-07-31: 1.2M2024-08-15: 1.1M2024-08-30: 1.1M2024-09-13: 1.0M2024-09-30: 1.1M2024-10-15: 1.1M2024-10-31: 1.1M2024-11-15: 977K2024-11-29: 985K2024-12-13: 1.1M2024-12-31: 1.1M2025-01-15: 1.1M2025-01-31: 1.2M2025-02-14: 1.4M2025-02-28: 1.6M
    the 28 Feb 2025 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 28 Jan 2025Filings record

    Director or officer change

  21. 10 Dec 2024Insiders record

    Raheja Manohar K. (EVP, Research & Development) bought 5,000 shares of SGHT ($19,250) (dated 9 Dec 2024)

  22. 6 Dec 2024Insiders record

    Raheja Manohar K. (EVP, Research & Development) bought 3,376 shares of SGHT ($13,133) (dated 5 Dec 2024)

  23. 4 Dec 2024Insiders record

    Raheja Manohar K. (EVP, Research & Development) bought 4,624 shares of SGHT ($18,450) (dated 3 Dec 2024)

  24. 22 Nov 2024Insiders record

    Raheja Manohar K. (EVP, Research & Development) bought 2,000 shares of SGHT ($7,400) (dated 21 Nov 2024)

  25. 22 Nov 2024Insiders record

    Encrantz Staffan (director) bought 551,802 shares of SGHT ($2.1M) (dated 21 Nov 2024)

  26. 7 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 7 Nov 2024Filings record

    Director or officer change

  28. 20 Oct 2024Lobbying record

    SIGHT SCIENCES: lobbying engagement terminated (FOLEY HOAG LLP) (dated 30 Sep 2024)

  29. 2 May 2024Filings record

    Completed an acquisition or asset sale

  30. 5 Apr 2024Lobbying record

    SIGHT SCIENCES: lobbying engagement terminated (PATEL PARTNERS) (dated 26 Mar 2024)

  31. 2 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 2 Feb 2024Filings record

    Director or officer change

  33. 1 Feb 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MMM']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12617243
  34. 23 Jan 2024Filings record

    A major agreement ended

  35. 26 Dec 2023Lobbying record

    SIGHT SCIENCES: new lobbying registration (PATEL PARTNERS) (dated 4 Dec 2023)

  36. 15 Dec 2023Lobbying record

    SIGHT SCIENCES: new lobbying registration (FOLEY HOAG LLP) (dated 8 Nov 2023)

  37. 2 Dec 2023Insiders record

    Encrantz Staffan (director) bought 144,000 shares of SGHT ($498,369) (dated 1 Dec 2023)

  38. 29 Nov 2023Insiders record

    Encrantz Staffan (director) bought 521,855 shares of SGHT ($1.8M) (dated 28 Nov 2023)

  39. 23 Nov 2023Insiders record

    Encrantz Staffan (director) bought 188,796 shares of SGHT ($450,812) (dated 22 Nov 2023)

  40. 21 Nov 2023Insiders record

    Encrantz Staffan (director) bought 127,003 shares of SGHT ($278,072) (dated 20 Nov 2023)

Showing the newest 40 of 72 entries; narrow the window or the kind of data to see older ones.

Not listed: 144 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001531177
Ticker
SGHT
Domain
sightsciences.com
Employer name
Sight Sciences, Inc. (1 unverified)
Hq location
CA|MENLO PARK|94025 (1 unverified)
Lobbying client
sight sciences
Name
Sight Sciences, Inc.
  • DOL H-1B labor condition applications and PERM certifications34 data points28 Feb 2022 to 2 Mar 2026
  • Federal lobbying disclosures (LDA)12 records, 54 data points10 Nov 2020 to 31 Mar 2026
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)87 records20 Jul 2017 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)455 data points31 Dec 2019 to 29 Oct 2026
  • SEC Form 4 insider transactions104 records, 192 data points21 Jul 2021 to 18 Nov 2026
  • FINRA short interest (twice monthly)377 data points30 Jul 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2692 data points15 Jul 2021 to 20 Nov 2026